The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AEGERION PHARMACEUTICALS INC | NOTE 2.000% 8/1 | 00767EAB8 | 73,570 | 95,045,000 | PRN | SOLE | 0 | 0 | 95,045,000 | ||
| PTC THERAPEUTICS INC | NOTE 3.000% 8/1 | 69366JAB7 | 43,752 | 46,567,000 | PRN | SOLE | 0 | 0 | 46,567,000 | ||
| VIVUS INC | NOTE 4.500% 5/0 | 928551AB6 | 34,040 | 46,000,000 | PRN | SOLE | 0 | 0 | 46,000,000 | ||
| VIVUS INC | NOTE 4.500% 5/0 | 928551AB6 | 10,360 | 14,000,000 | PRN | DFND | 0 | 0 | 14,000,000 | ||
| APOLLO ENDOSURGERY INC | COM | 03767D108 | 1,580 | 252,079 | SH | SOLE | 252,079 | 0 | 0 | ||